The Latest Analyst Coverage For Alexandria Real Estate Equities, Inc. (ARE), Healthcare Trust of America, Inc. (HTA)

Alexandria Real Estate Equities, Inc. (NYSE:ARE) shares were trading lower by -1.07 percent ($-1.28) at $118.06 a piece in Friday’s session. It had closed the previous session at $119.34. ARE trades with a P/S ratio of 10.92. This is lower than the both industry’s 83.88 and the wider sector’s 13.65. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 58.74 and a trailing 12-month price-earnings (P/E) multiple of 294.41. Shares of ARE have downtrended -2.11% in the past three months, while the S&P 500 has moved -4.61% in that time. Alexandria Real Estate Equities, Inc. (ARE) has a market cap of $11.17 billion and over the last 12 months, Alexandria Real Estate Equities, Inc. (NYSE:ARE) has gone stronger by 4.45%. During the last 52 weeks, the (NYSE:ARE) price has been as high as $123.89 and as low as $101.51. Alexandria Real Estate Equities, Inc. earnings have declined with an annualized rate of -27.7% over the last 5 years.

Alexandria Real Estate Equities, Inc. (Mean Target Price: $126.92)

The average 1-year price target for Alexandria Real Estate Equities, Inc. (ARE) — averaging the work of different analysts — reveals a mean PT of $126.92/share. That’s a potential 7.5 increase relative to where Alexandria Real Estate Equities, Inc. (NYSE:ARE) has been trading recently. The current price is seen ranging between $117.76 and $120.1. There are brokerage firms with lower targets than the average, including one setting a price target of $117. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $140.

Alexandria Real Estate Equities, Inc. (ARE) Consensus Recommendation

The collective rating of 2.3 for Alexandria Real Estate Equities, Inc. (NYSE:ARE) also leans strongly towards the neutral end of the spectrum. Of the 12 analysts surveyed by Reuters that track ARE 5 of them rate its stock a hold. The other 7, though not evenly; between analysts who think you should buy Alexandria Real Estate Equities, Inc. versus those who think you should sell it. A 7 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of ARE or, if they already own its stock, sell it.

Is Healthcare Trust of America, Inc. (NYSE:HTA) Cheap From Peers?

Healthcare Trust of America, Inc. (HTA) knifed -1.13 percent lower and now trades for $29.81. HTA comes in with a P/S ratio of 11.99 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (13.65) and its peers (83.88). Also, it has an estimated price-earnings (P/E) multiple of 64.66 and a trailing 12-month price-earnings (P/E) multiple of 137.37. During the last 52 weeks, the price has been as high as $34.35 and as low as $26.34. Healthcare Trust of America, Inc. (NYSE:HTA) earnings have risen with a quarterly rate of 11.1% over the last 5 years. Shares of HTA have sank -8.42% in the past three monthswhile the S&P 500 has dropped -10.76% in that time.

Healthcare Trust of America, Inc. (Price Objective: $34.04)

Healthcare Trust of America, Inc. (NYSE:HTA) has a market cap of $6.05 billion and over the last 12 months, HTA has declined by -11.54%. The average 1-year price target for (HTA) reveals an average price target of $34.04 per share. That’s a potential 14.19 gain from where (NYSE:HTA) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $30. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $36.

Analyst Thoughts About Healthcare Trust of America, Inc. (NYSE:HTA)

The consensus recommendation — averaging the work of 12 analysts — of 1.8 for Healthcare Trust of America, Inc. (HTA) points to bullish case. Of the analysts surveyed by Reuters that track Healthcare Trust of America, Inc. 3 of them rate its stock a hold. The other 9 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 9 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:HTA) or, if they already own its stock, sell it.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

4 + ten =